Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Completed · Phase 2

Conditions studied: Age-Related Macular Degeneration

In brief

Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment.

Key facts

Study ID

NCT02357342

Run by

Maturi, Raj K., M.D., P.C.

People needed

40

Starts

2015-04-01

Expected to finish

2017-01-01

Last updated by the study team

2017-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• best corrected visual acuity of 5-65, inclusive, in study eye
• presence of choroid neovascularization secondary to AMD
• persistent edema despite at least 3 previous intravitreal anti-VEGF injections in the past 5 months

You may not qualify if…

• greater than 100 micron decrease in central subfield thickness on Optical Coherence Topography (OCT) since last standard of care visit
• history of major ophthalmic surgery in the study eye in the past 3 months
• history of significant ocular disease or condition other than exudative AMD that may confound results

Where it is running

• Raj K Maturi MD PC — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.